Undervalued Stock Case Could Reshape Zimmer Biomet (ZBH)

• Zimmer Biomet Holdings is currently flagged as undervalued on several measures, with P/E, P/B and P/CF ratios sitting below industry averages and paired with what independent analysis describes as a favorable earnings outlook.
• The combination of a value tilt and earnings support suggests Zimmer Biomet may appeal to investors focused on company fundamentals such as cash generation, margins and capital allocation rather than short term sentiment.
• We will now assess how this perceived undervaluation alongside a supportive earnings outlook could reshape Zimmer Biomet’s broader investment narrative.

Scan for more opportunities with similar traits to Zimmer Biomet Holdings by reviewing the hand picked 29 high quality undervalued stocks that combine compressed valuations with solid underlying fundamentals.

Zimmer Biomet Holdings Investment Narrative Recap

To own Zimmer Biomet Holdings, you need to believe the orthopedic procedures market, including hips, knees and related technologies, keeps providing steady case volumes for its implants and digital systems. The short term swing factor is execution on Project Optima and the broader commercial refresh in the U.S., which aims to convert that procedure flow into more efficient territory coverage and healthier unit economics.

The biggest near term risk still sits on the cost side. Management is dealing with pricing pressure, higher manufacturing expenses and a manufacturing network reshuffle that already coincides with lower gross and operating margins. The recent value focused attention on Zimmer Biomet does not materially change those operational challenges.

Recent communication around manufacturing network optimization is one of the more important developments for this Zimmer Biomet story, even if it is not directly tied to the latest valuation focused news. Management plans to reduce up to 580 jobs in Switzerland while building out a new plant in Costa Rica, which changes the footprint of how products are made and supplied.

For investors, that restructuring feeds directly into both the key catalyst and the core risk. A successful Costa Rica ramp and the shift of some R&D to India could reset the cost base and support margins, while missteps could extend restructuring charges, create supply hiccups and limit the benefit of any improvement in sales or earnings trends that underpins the current undervaluation argument.

Zimmer Biomet Holdings Forecasts Behind the Undervaluation Story

The current undervaluation debate around Zimmer Biomet Holdings rests on a specific set of analyst forecasts rather than vague optimism. Revenue is projected to grow by 3.4% a year over the next three years, while profit margins are expected to move from 9.5% today to 13.6% in that same window. On top of that, analysts see earnings rising from US$806.7 million today to US$1.3b by 2029, with the most optimistic forecasts at US$1.5b and the most cautious at US$1.1b. This shows there is meaningful disagreement around how the execution story plays out.

Zimmer Biomet Holdings' narrative projects US$9.4b revenue and US$1.3b earnings by 2029. This assumes 3.4% yearly revenue growth and an earnings increase of about US$493 million from current earnings of US$806.7 million.

Those income projections also feed directly into how analysts are thinking about the share price today. The consensus view is that Zimmer Biomet would need to be trading on a P/E of 18.1x in 2029 for those US$1.3b earnings to line up with current price targets, compared with a multiple of 22.5x today and an industry level quoted at 24.8x. For readers, that means the story is not just about earnings rising. It is also about the market being willing to accept a lower multiple on those projected profits than it does now or than it currently does for the broader U.S. medical equipment group.

On the top line, the forecast for Zimmer Biomet implies annual growth layered on top of a reshaped product mix and footprint rather than a sharp surge in sales. A 3.4% yearly increase in turnover, paired with higher targeted margins, suggests analysts are giving weight to cost structure shifts such as the Costa Rica plant and the Indian global capability center. The expectation that margins could move from 9.5% to 13.6% over three years effectively embeds a material lift in operating efficiency into the valuation argument.

Earnings mechanics also reflect share count assumptions that investors should not overlook. Analysts expect Zimmer Biomet to reduce its number of shares outstanding by about 3.76% each year over the next three years. That buyback driven shrink in the share base can support earnings per share metrics even if net income trends are relatively steady, which helps explain how consensus arrives at earnings per share of US$6.58 by around 2029 on the US$1.3b profit figure.

Those inputs combine into the current set of price targets on Zimmer Biomet Holdings. The average analyst target sits at US$107.57, compared with a recent share price of US$95.36, with individual expectations ranging from US$93 on the low end to US$130 at the top. That spread reflects different views on how effectively management can push through the commercial overhaul, absorb higher manufacturing and restructuring costs, and still get margins closer to the 13.6% mark that the forecasts assume.

Uncover why Zimmer Biomet Holdings' fair value indicates a 17% potential upside to its current price that could narrow quickly.

Exploring Other Perspectives

Simply Wall St Community members offer three fair value views on Zimmer Biomet, ranging from US$107.57 at the low end to an aggressive US$262.81 at the high end. That spread shows how far opinions can stretch. Some focus on Project Optima, technology categories and portfolio additions as potential tailwinds, while others worry about pricing pressure and manufacturing execution. Treat these as starting points and explore several of these alternative perspectives before forming a view.

Explore 2 other Zimmer Biomet Holdings fair value estimates, including one that suggests potential upside of as much as 185% from the current price!

Form Your Own Verdict

Don't just follow the ticker, dig into the data and build a conviction that's truly your own.

• A great starting point for your Zimmer Biomet Holdings research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• See our latest analysis for Zimmer Biomet Holdings. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Zimmer Biomet Holdings' overall financial health at a glance.

Looking For More Investment Ideas Beyond Zimmer Biomet Holdings?

Once you have formed a view on Zimmer Biomet Holdings, it can help to line it up against other opportunities that share similar traits or offer very different risk and return profiles. The Simply Wall St Screener lets you move from a single stock story to a broader watchlist built around the characteristics you care about most.

• If you want income to play a bigger role in your portfolio, start with sturdy payers and review the 8 dividend fortresses that may help you balance yield with stability.
• For readers who prefer financial resilience over excitement, you can filter for sturdier balance sheets and steady fundamentals using the list of solid balance sheet and fundamentals (25 results) to pressure test your risk tolerance.
• If you are hunting for less crowded opportunities, you can cast a wider net with the 20 high quality undiscovered gems that highlight under followed companies with strong underlying metrics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com